The goal of this study is to obtain baseline information on serum and cerebrospinal fluid (CSF) relaxin and Sema4A levels in patients with MS, as well as to further study RXFP-1 receptor binding affinity for RLX in patients with active and clinically stable MS, and further characterize the role of Sema4A in MS patients.
This study will evaluate relaxin (RLX) and Semaphorin 4A (Sema4A) levels in patients with multiple sclerosis.